Private equity gets serious about drug development

Private equity is going shopping, and biotech venture funds are on the list. Three deals in the past few months suggest this to be true: EQT’s acquisition of LSP, Carlyle’s Abingworth buyout and, most recently, Sofinnova’s sale of a minority stake to Apollo.